Calcitonin-Salmon (Calcitonin,Salmon,Synthetic) Patent Expiration, LOE Window & CMS Spending
Calcitonin-Salmon (Calcitonin,Salmon,Synthetic) by Apotex: Off-Patent Genericized (AB Competition), 2 AB generics, $15.2M 2024 CMS Part D & Medicaid spend, and $2,661 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Apotex |
| FDA Application & Pathway | Reconciled (UNLINKED) |
| Exclusivity / Cliff Horizon | Off-Patent Genericized (AB Competition) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | Not listed / N/A |
| Orange Book Patents (*PED Extensions) | 0 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 2 |
| 2024 CMS Total Public Spend | $15.2M |
| 2024 Medicare Part D Spend | $14.1M |
| 2024 Medicaid Spend | $1.1M |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,661 intro WAC) |